# A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

> **NCT04657016** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 579 (actual)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Tirzepatide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04657016
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2023-04-20
- **Final completion:** 2023-05-12
- **Target enrollment:** 579 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657016, "A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04657016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*